Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

CHMP Readies ‘Outstanding Issues’ Lists For Products Nearing EU Review End

Executive Summary

Baxter, Ariad, Diurnal. Kyowa Kirin and AB Science are among the companies that will shortly find out what remaining concerns the European Medicines Agency’s key advisory panel, the CHMP, has regarding products of theirs that are under review.

Advertisement

Related Content

Ocrevus Tries Again For EU Approval Nod
Helsinn And AB Science Persevere In EU Despite CHMP Setback
FDA Approval Round Up: Keytruda, Opdivo Add Claims
Keeping Track: Breakthrough Therapies Becoming Breakthrough Applications For Tezacaftor, Burosumab, Emicizumab
Brigatinib Approval Validates Ariad Buy, But Can Takeda Carve A Position?
Blockbuster Competitors Figure Large Among Biosimilars Under Review in EU
Hypogonadism Trial Designs: FDA Panel Favors Symptom Assessments, Fertility Measures
Diurnal Nears Market With Novel Adrenal Insufficiency Products
Repros Therapeutics Needs New Pivotal Trial For Low T Drug Enclomiphene

Topics

Related Companies

Related Deals

What to read next

Advertisement
UsernamePublicRestriction

Register

PS121739

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel